摘要
目的观察含奥沙利铂方案经导管肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效。方法回顾性分析2008年9月至2010年9月收治的94例原发性肝癌患者的临床资料,所有患者随机分为两组,观察组患者采用奥沙利铂联合吉西他滨进行TACE治疗,对照组采用注射用盐酸多柔比星为主进行TACE治疗,并进行疗效及不良反应评价。结果观察组的近期有效率为61.70%高于对照组的31.91%(P<0.05);在远期疗效上,观察组在1年内的病死率低于对照组(P<0.05),在两年内的病死率差异不显著;对照组的不良反应与观察组差异不显著,其胃肠道不良反应率高于观察组(P<0.05),神经系统毒性又低于观察组(P<0.05)。结论在不增加不良反应的基础上,含奥沙利铂方案TACE治疗原发性肝癌的近期疗效明显,值得推广应用。
Objective The efficacy and adverse reactions of TACE including oxaliplatin for the treatment of primary hepatic carcinoma were discussed.Methods The clinical data of patients with primary liver cancer treated in this hospital from September 2008 to September 2010 were retrospectively analyzed,all these patients were randomly divided into two groups,patients in observation group were treated with oxaliplatin in combination with gemcitabine for TACE treatment,and patients in control group were treated with doxorubicin-based TACE treatment,and the evaluation of the efficacy and adverse reactions had been carried out.Results The short term efficacy in observation group was 61.70 %,it was higher than that of control group（31.91%）（P 0.05）;the long-term efficacy in observation group in one year mortality rate was better than that of control group（P 0.05）,and the difference in two years mortality was not significant;and the difference in incidence of adverse reactions in control group and observation group was not significant,but the rate of gastrointestinal adverse reactions in control group was higher than that of observation group（P 0.05）,and its nervous system toxicity was lower than that of observation group（P 0.05）.Conclusion On the basis of not increase in adverse reactions,the short-term efficacy of TACE treatment of primary liver cancer with oxaliplatin is obvious,and it is worthy to be recommended for further application.
出处
《临床和实验医学杂志》
2013年第11期856-857,共2页
Journal of Clinical and Experimental Medicine
